Am J Transplant, Volume 17, Suppl 3 Archives - Page 142 of 181 - ATC Abstracts

2017 American Transplant Congress
Sequential Monitoring of Natural Killer Cell Reconstitution Against CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation.
P. Ki Hyun,¹ L. Hyeyoung,² R. Ji Hyeong,¹ K. Yonggoo,² H. Kyungja,² C. Byung Sik,² K. Hee-Je,³ M. Woosung,³ O. Eun-Jee.²
¹Department of Biomedical Science, Graduate School, the Catholic University of Korea, Seoul, Korea; ²Department of Laboratory Medicine, the Catholic University of Korea, Seoul, Korea; ³Department of Internal Medicine, the Catholic University of Korea, Seoul, Korea
Cytomegalovirus (CMV) reactivation has an impact on significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Natural killer (NK) cells are the first…
2017 American Transplant Congress
Immediate vs Delayed Initiation of CMV Prophylaxis…Safe and Cost Beneficial?
L. Cotiguala, A. Carlson, C. Truax, B. Sirandas, I. Hall, L. Smith.
University of Utah Health Care, Salt Lake City, UT
Background: Recommendations differ on when to initiate valganciclovir (VGCV) for CMV prophylaxis (ppx) after tx. Current labeling states within 10 days of tx. We evaluated…
2017 American Transplant Congress
Effect of Influenza Vaccination in the Severity of Illness in Hospitalized Transplant Recipients with Laboratory-Confirmed Influenza.
A. Bagenski,¹ F. Silveira.²
¹Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Medicine, University of Pittsburgh, Pittsburgh, PA
Objectives: The effectiveness of influenza vaccine in solid organ transplant (SOT) recipients may be decreased due to immunosuppression. Some studies have suggested that influenza vaccination…
2017 American Transplant Congress
Is Thymic Function Determining Rejection Onset in Heart Transplantation?
A. Sannier,^1,2 R. Dorent,^1,3 M. Le Borgne,¹ N. Stroumza,¹ J. Senemaud,¹ L. Louedec,¹ F. Andreata,¹ A. Gaston,¹ C. Deschildre,¹ P. Nataf,^1,3 A. Couvelard,² G. Caligiuri,¹ A. Nicoletti.¹
¹Inserm U1148, Diderot University, Paris, France; ²Pathology Department, Bichat Hospital, Paris, France; ³Cardiac Surgery Department, Bichat Hospital, Paris, France
The thymus is the primary site of T cell development, involuting into fatty tissue in adults. Thymic function persists in the adulthood and may be…
2017 American Transplant Congress
Donor Macrophage Depletion from CMV-Latently Infected Hearts Abrogates CMV-Accelerated Chronic Rejection.
J. Burg,¹ T. Andoh,² N. Haese,² I. Jones,² S. Orloff,¹ D. Streblow.²
¹Department of Surgery, OHSU, Portland, OR; ²VGTI, OHSU, Hillsboro, OR
Purpose: Latent donor CMV infection has been shown to accelerate chronic rejection (CR) in a heterotopic rat heart transplant model. CMV latency is associated with…
2017 American Transplant Congress
Assessment of Cardiosphere-Derived Cell Exosomes as Possible Modulator of Alloimmunity in a Mouse Model of HLA-A2 Allosensitization.
I. Kim,¹ G. Wu,¹ N.-N. Chai,¹ G. De Couto,² E. Marban,² A. Klein,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Mounting data indicate that exosomes, a nanosized membrane particle secreted by cells has immune regulatory properties, including anti-inflammation and mediating autocrine, paracrine, and endocrine…
2017 American Transplant Congress
Clinical and Molecular Significance of Microvascular Inflammation Negative Transplant Glomerulopathy.
M. Lubetzky,¹ N. Hayde,¹ P. O Broin,² Y. Bao,¹ E. Akalin.¹
¹Montefiore Medical Center, Bronx; ²National University of Ireland Galway University, Galaway, Ireland
Transplant glomerulopathy (TGP) with donor specific antibodies (DSA) and microvascular inflammation (MVI) is due to chronic antibody mediated rejection (CAMR). We reported previously that intragraft…
2017 American Transplant Congress
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).
B.-H. Shin,¹ M. Everly,² J. Choi,¹ S. Ge,¹ A. Petrosyan,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Terasaki Foundation Laboratory, Los Angeles
Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…
2017 American Transplant Congress
Vancomycin Prophylaxis for Prevention of Clostridium difficile Recurrence in Renal Transplant Patients.
L. Spliner,¹ J. Fose,¹ G. Leverson,² J. Smith,³ C. Saddler,³ M. Jorgenson.¹
¹Pharmacy, UW Health, Madison, WI; ²Surgery, UW Health, Madison, WI; ³Medicine, UW Health, Madison, WI
Purpose: Clostridium difficile infection (CDI) is higher in solid organ transplant recipients. IDSA/SHEA guidelines do not recommend prophylactic (PROPH) vancomycin (VANC) or metronidazole in CDI…
2017 American Transplant Congress
Incidence of Fungal and Viral Infections Following Rituximab Use in Kidney Transplant Recipients.
L. Wong, M. Ison, C. Richardson, K. Cunningham, C. D'Agostino, C. Tseng, A. Shetty.
Northwestern Memorial Hospital, Chicago, IL
Rituximab is used off-label in solid organ transplant for desensitization and treatment of antibody-mediated rejection (AMR). It targets CD20 and results in B cell depletion.…